Table 1.
Association results (P<10−6) in novel AD loci among APOE ε4− subjects in the combined stage 1 and stage 2 samples.
| SNP | CH | Region or Closest Gene | MA | MAF | Stage 1
|
Stage 2
|
Stages 1 + 2
|
|||
|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | |||||
| rs16847609 | 3 | SOX14/CLDN18 | A | 0.09 | 1.21 (1.12–1.29) | 2.3x10−7 | 1.09 (0.87–1.37) | 0.47 | 1.19 (1.11–1.28) | 5.3x10−7 |
| rs382216 | 5 | CDC42SE2-ACSL6 | T | 0.36 | 0.88 (0.83–0.93) | 6.5x10−6 | 0.78 (0.67–0.91) | 0.002 | 0.87 (0.82–0.92) | 2.0x10−7 |
| rs11168036 | 5 | PFDN1/HBEGF | T | 0.50 | 1.14 (1.09–1.19) | 9.3x10−9 | 0.97 (0.85–1.11) | 0.64 | 1.12 (1.07–1.17) | 3.2x10−7 |
| rs2732703 | 17 | KANSL1/LRRC37A | G | 0.13 | 0.73 (0.65–0.83) | 6.4x10−7 | 0.71 (0.58–0.88) | 0.001 | 0.73 (0.65–0.81) | 5.8x10−9 |
| rs71380849 | 17 | CDR2L | A | 0.06 | 1.45 (1.24–1.70) | 3.8x10−6 | 1.59 (1.01–2.50) | 0.04 | 1.47 (1.26–1.71) | 9.1x10−7 |